



Biomarkers and Algorithms for the Diagnosis of Vitamin B₁₂ Deficiency

Luciana Hannibal^{1*}, Vegard Lysne², Anne-Lise Bjørke-Monsen³, Sidney Behringer¹, Sarah C. Grünert¹, Ute Spiekerkoetter¹, Donald W. Jacobsen⁴ and Henk J. Blom¹

¹ Laboratory of Clinical Biochemistry and Metabolism, Department for Pediatrics, Medical Center, University of Freiburg, Freiburg, Germany, ² Department of Clinical Sciences, University of Bergen, Bergen, Norway, ³ Department of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway, ⁴ Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

OPEN ACCESS

Edited by:

Thomas Nägele,
University of Vienna, Austria

Reviewed by:

Andrea Fuso,
Sapienza University of Rome, Italy
Matej Oresic,
University of Turku, Finland

*Correspondence:

Luciana Hannibal
luciana.hannibal@uniklinik-freiburg.de

Specialty section:

This article was submitted to
Metabolomics,
a section of the journal
Frontiers in Molecular Biosciences

Received: 15 April 2016

Accepted: 07 June 2016

Published: 27 June 2016

Citation:

Hannibal L, Lysne V, Bjørke-Monsen A-L, Behringer S, Grünert SC, Spiekerkoetter U, Jacobsen DW and Blom HJ (2016) Biomarkers and Algorithms for the Diagnosis of Vitamin B₁₂ Deficiency. *Front. Mol. Biosci.* 3:27. doi: 10.3389/fmolb.2016.00027

Vitamin B₁₂ (cobalamin, Cbl, B₁₂) is an indispensable water-soluble micronutrient that serves as a coenzyme for cytosolic methionine synthase (MS) and mitochondrial methylmalonyl-CoA mutase (MCM). Deficiency of Cbl, whether nutritional or due to inborn errors of Cbl metabolism, inactivate MS and MCM leading to the accumulation of homocysteine (Hcy) and methylmalonic acid (MMA), respectively. In conjunction with total B₁₂ and its bioactive protein-bound form, holo-transcobalamin (holo-TC), Hcy, and MMA are the preferred serum biomarkers utilized to determine B₁₂ status. Clinically, vitamin B₁₂ deficiency leads to neurological deterioration and megaloblastic anemia, and, if left untreated, to death. Subclinical vitamin B₁₂ deficiency (usually defined as a total serum B₁₂ of <200 pmol/L) presents asymptotically or with rather subtle generic symptoms that oftentimes are mistakenly ascribed to unrelated disorders. Numerous studies have now established that serum vitamin B₁₂ has limited diagnostic value as a stand-alone marker. Low serum levels of vitamin B₁₂ not always represent deficiency, and likewise, severe functional deficiency of the micronutrient has been documented in the presence of normal and even high levels of serum vitamin B₁₂. This review discusses the usefulness and limitations of current biomarkers of B₁₂ status in newborn screening, infant and adult diagnostics, the algorithms utilized to diagnose B₁₂ deficiency and unusual findings of vitamin B₁₂ status in various human disorders.

Keywords: vitamin B₁₂, cobalamin, homocysteine, methylmalonic acid, holo-transcobalamin, diagnostic algorithm, functional deficiency of B₁₂

VITAMIN B₁₂ DEFICIENCY

Vitamin B₁₂ (B₁₂ = Cbl, “cobalamin,” the chemical name) is an essential water-soluble micronutrient required by all cells in the body. Humans are unable to synthesize B₁₂ and thus rely on dietary intakes and a complex intracellular route for vitamin processing and delivery to its target destinations (**Figure 1**) (Hannibal et al., 2009). Vitamin B₁₂ deficiency due to malabsorption and inadequate intake is a public health issue worldwide. It is estimated that 15–20% of the elderly in the United States are B₁₂ deficient (Allen, 2009). In Germany, about 10% of the male elderly population

and 26% of the female elderly population present with insufficient levels of vitamin B₁₂ (Hartmann, 2008; Grober et al., 2013). In India, ~75% of the population, i.e., over 650 million people, have B₁₂ deficiency (Antony, 2001; Refsum et al., 2001), which can only be partly ascribed to a vegetarian diet in a substantial portion of the population.

Vitamin B₁₂ deficiency is a multifactorial condition caused by insufficient intake (nutritional deficiency) as well as acquired or inherited defects that disrupt B₁₂ absorption, processing and trafficking pathways (functional deficiency). Methylcobalamin (MeCbl) serves as a coenzyme for the biosynthesis of methionine from homocysteine catalyzed by the cytosolic enzyme methionine synthase (MS). This reaction regenerates tetrahydrofolate (THF) from N⁵-methyl-tetrahydrofolate (N⁵-CH₃-THF), which is essential for the *de novo* biosynthesis of nucleic acids. Adenosylcobalamin (AdoCbl) is required for the conversion of methylmalonyl-CoA to succinyl-CoA catalyzed by mitochondrial methylmalonyl-CoA synthase (MCM), an anaplerotic reaction that furnishes increased demands for the Krebs cycle and heme biosynthesis precursor succinyl-CoA.

Insufficient supply of B₁₂ and genetic defects impairing its cellular processing and trafficking lead to the accumulation of homocysteine (Hcy) and methylmalonic acid (MMA), which enter circulation and give rise to hyperhomocystinemia and methylmalonic acidemia.

The recommended daily dose of B₁₂ for adults is 2.4 μg per day (Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline, 1998), which is equivalent to the daily intake in the normal western diet. Malabsorption due to aging, poor nutrition and acquired defects in vitamin B₁₂ metabolism are the leading causes of vitamin B₁₂ deficiency worldwide. Inborn errors of vitamin B₁₂ metabolism are rare.

Vitamin B₁₂ deficiency is frequently under-diagnosed in pregnancy and in infants from mothers having insufficient levels of the micronutrient (Wheeler, 2008; Sarafoglou et al., 2011). Ensuring sufficient intake of vitamin B₁₂ during pre-conception, pregnancy, and post-partum is strongly recommended (Bjørke Mønsen et al., 2001; Rasmussen et al., 2001; Bjørke-Mønsen et al., 2008; Hinton et al., 2010; Dayaldasani et al., 2014). Other populations at risk of developing vitamin B₁₂ deficiency include the elderly, vegetarians and vegans, recipients of bariatric surgery (Majumder et al., 2013; Kwon et al., 2014) as well as those suffering from gastrointestinal diseases featuring ileal resections >20 cm (Battat et al., 2014). Certain medications such as metformin (Greibe et al., 2013b; Aroda et al., 2016) and proton-pump inhibitors (Howden, 2000; Wilhelm et al., 2013) may also transiently induce a status of cobalamin deficiency, which may be reversible upon completion of treatment and/or with oral vitamin B₁₂ supplementation.

Herein, we discuss three aspects of the assessment of B₁₂ status: (1) The utility of metabolites used as biomarkers of vitamin B₁₂ deficiency in neonates and adults, (2) The algorithms employed to predict subclinical and clinical B₁₂ deficiency, and

(3) Major challenges and diagnosis of vitamin B₁₂ deficiency in special populations.


SERUM BIOMARKERS OF VITAMIN B₁₂ DEFICIENCY: STRENGTHS AND LIMITATIONS

Total Serum Vitamin B₁₂

The most direct assessment and perhaps preferred first-assay to determine vitamin B₁₂ status is the measurement of total serum vitamin B₁₂. This assay is widely available in clinical chemistry laboratories. Ranges for normal (>250 pmol/L), low (150–249 pmol/L), and acute deficiency (<149 pmol/L) vitamin B₁₂ have been defined and are used in most clinical chemistry laboratories worldwide (Clarke et al., 2003; Selhub et al., 2008; Mirkazemi et al., 2012). One limitation of this biomarker is that it assesses total circulating vitamin B₁₂, of which ~80% is bound to haptocorrin, and therefore, not bioavailable for cellular uptake. Another limitation of this assay lies in its unreliability to reflect cellular vitamin B₁₂ status. Results from studies assessing serum and cellular vitamin B₁₂ have shown that the levels of serum B₁₂ do not always represent cellular B₁₂ status (Carmel, 2000; Solomon, 2005; Devalia et al., 2014; Lysne et al., 2016). In particular, patients with inborn errors of vitamin B₁₂ metabolism can present with normal or low serum values of the vitamin, while being deficient at the cellular level. Furthermore, functional vitamin B₁₂ deficiency due to oxidative stress has been identified in elders exhibiting normal values of serum vitamin B₁₂ (Solomon, 2015). Functional deficiency of vitamin B₁₂ was corrected upon supplementation with cyanocobalamin (CNCbl), as judged by reduction in the serum levels of tHcy and MMA (Solomon, 2015). Thus, total serum B₁₂ is not a reliable biomarker of vitamin B₁₂ status when used alone. Nonetheless, this marker should not be considered obsolete as a number of studies show that total serum vitamin B₁₂ may be helpful to predict prognosis and status of diseases featuring abnormally high vitamin B₁₂ levels in serum (>650 pmol/L), such as cancer (Arendt et al., 2016) and autoimmune lymphoproliferative syndrome (ALPS) (Bowen et al., 2012).

Homocysteine

Homocysteine is a metabolite of one-carbon metabolism that is remethylated by MeCbl-dependent MS or betaine-homocysteine methyltransferase as part of the methionine cycle (Finkelstein and Martin, 1984) and degraded by cystathionine β-synthase (CBS) in the transsulfuration pathway (Figure 2). Conversion of Hcy to Met by MS depends on the availability of both vitamin B₁₂ and folate (as N⁵-CH₃-THF), and therefore, nutritional deficiencies in either one of these micronutrients lead to the accumulation of Hcy in serum and urine. Likewise, inborn errors of metabolism that impair the upstream processing and trafficking of B₁₂ or folate lead to elevation of this metabolite, a condition collectively known as hyperhomocystinemia. The normal range of total plasma Hcy (tHcy) in human plasma is 5–15 μmol/L (Ueland et al., 1993) and values >13 μmol/L may be



considered elevated in adults (Jacques et al., 1999). Homocysteine levels are always higher in serum compared to plasma due to the release of Hcy bound to cellular components (Jacobsen et al., 1994). Hence, plasma and not serum should be used to determine the levels of tHcy. Although gender and age reference intervals have been established in some studies (Jacobsen et al., 1994; Rasmussen et al., 1996; van Beynum et al., 2005), they are usually ignored in the reporting of tHcy levels. Because of the dual biochemical origin of elevated Hcy, this biomarker is of limited value to assess vitamin B₁₂ status as a stand-alone measurement. This is also true for the newborn screening of inborn errors of vitamin B₁₂ metabolism found in the cblD, cblF, and cblJ (Huemer et al., 2015) disorders.


Methylmalonic Acid

MMA increases upon inactivation of AdoCbl-dependent MCM in the mitochondrion. Nutritional and functional deficiencies of vitamin B₁₂ result in the inactivation of MCM leading to buildup of its substrate methylmalonyl-CoA, which enters circulation as free MMA. The reaction catalyzed by MCM (Figure 2) is not affected by other vitamins of one-carbon metabolism, and

therefore, MMA is considered a more specific marker of vitamin B₁₂ deficiency (Clarke et al., 2003). Serum values of MMA, ranging from >260 to 350 nmol/L indicate elevation of this metabolite (Clarke et al., 2003). Nonetheless, there are few pathologies such as renal insufficiency that lead to an increase in MMA (Iqbal et al., 2013). For example, one study showed that 15–30% of individuals with high vitamin B₁₂ concentrations in serum also had elevated MMA concentrations, which may reflect renal dysfunction instead of authentic vitamin B₁₂ deficiency (Clarke et al., 2003). Thus, the utility of this marker should be considered carefully in older patients and patients with suspected or established renal disease. Assessment of a second marker of vitamin B₁₂ status, such as holo-transcobalamin (holo-TC) (Iqbal et al., 2013) should be considered. Another study showed that the clearance of both Hcy and MMA may be compromised in patients with reduced kidney function (Lewerin et al., 2007).

Total Serum Holo-Transcobalamin

Dietary B₁₂ is transported in the digestive system via the use of three protein transporters that bind the micronutrient in a sequential fashion, following the order haptocorrin (HC),



intrinsic factor (IF), and transcobalamin (TC) (Fedosov et al., 2007; Fedosov, 2012). After absorption in the intestine, vitamin B₁₂ bound to TC (holo-TC) reaches circulation and it is distributed to every cell in the body. Cells take up holo-TC via receptor-mediated endocytosis, aided by the transcobalamin receptor (TCbR; CD320) (Quadros et al., 2009). Because the only fraction of dietary vitamin B₁₂ that is bioavailable for systemic distribution is in the form of holo-TC (Valente et al., 2011), the level of holo-TC in serum has been successfully utilized as a marker of bioactive vitamin B₁₂ (Nexo et al., 2000, 2002; Valente et al., 2011; Yetley et al., 2011). Holo-TC represents 6–20% of the total vitamin B₁₂ present in serum (Nexo et al., 2000, 2002; Valente et al., 2011; Yetley et al., 2011). This marker is more accurate in assessing the biologically active fraction of vitamin B₁₂ in circulation than serum B₁₂ itself, and its level correlates well with the concentration of vitamin B₁₂ in erythrocytes (Valente et al., 2011). The diagnostic value of holo-TC has proven superior to Hcy and MMA for the assessment

of vitamin B₁₂ status in the elderly (Valente et al., 2011). The normal range of holo-TC in healthy subjects is 20–125 pmol/L (Valente et al., 2011). Additional research is needed to elucidate the mechanisms that control holo-TC homeostasis in the normal population and in pathologies that alter vitamin B₁₂ transport and utilization. For example, abnormally low levels of holo-TC have been documented in patients receiving chemotherapy, macrocytosis and in individuals carrying the TC polymorphism 67A>G, without vitamin B₁₂ deficiency (Vu et al., 1993; Wickramasinghe and Ratnayaka, 1996; Riedel et al., 2005, 2011). Insufficient sensitivity (44%) of holo-TC as a marker of vitamin B₁₂ status was noted in a cohort of 218 institutionalized elderly patients (Palacios et al., 2013). At present time, it is unknown whether and how holo-TC levels vary in patients harboring inborn errors affecting intracellular vitamin B₁₂ metabolism (cblA-cblJ). Thus, the diagnostic value of holo-TC as a first line test awaits further investigation.

Propionylcarnitine (C3) and its Ratios with Acetylcarnitine (C3/C2) and Palmitoylcarnitine (C3/C16)

In addition to the four canonical markers discussed above, vitamin B₁₂ deficiency leads to accumulation of propionylcarnitine (C3) (Sarafoglou et al., 2011), which is a marker of methylmalonic aciduria and propionic acidemia. While vitamin B₁₂ deficiency is not a primary test in newborn screening programs, a study showed that markers C3, C3/C2, and C3/C16 exhibit a negative correlation with maternal levels of vitamin B₁₂ in the first trimester of pregnancy, and thus may bear diagnostic value (Dayaldasani et al., 2014). Although this finding requires further investigation with respect to the functional biomarkers Hcy and MMA, the finding opens the possibility of early identification of vitamin B₁₂ insufficiency or deficiency during the first trimester of pregnancy and adequate treatment.

ALGORITHMS FOR THE DIAGNOSIS OF VITAMIN B₁₂ DEFICIENCY

According to the World Health Organization (WHO), vitamin B₁₂ status in adults is defined by the serum levels of the micronutrient with the following cut-offs and definitions: >221 pmol/L is vitamin “B₁₂ adequacy”; between 148 and 221 pmol/L is “low B₁₂,” and lower than 148 pmol/L is “B₁₂ deficiency” (de Benoist, 2008; Allen, 2009). However, stand-alone markers of B₁₂ status, such as serum B₁₂, have proven insufficient for the unequivocal diagnosis of vitamin B₁₂ deficiency (Fedosov, 2013; Palacios et al., 2013; Remacha et al., 2014; Fedosov et al., 2015). Further, the WHO criterion does not account for age effects. Algorithms that combine a minimum of two biomarkers have been employed worldwide, each exhibiting advantages and disadvantages (Palacios et al., 2013; Remacha et al., 2014).

A study performed on a Swedish population proposed that when physicians request testing for suspected vitamin B₁₂ or folate deficiency, the first-line test of choice should be tHcy, and only when tHcy > 9 μM, should additional markers be tested to discriminate between vitamin B₁₂ and folate deficiencies (Schedvin et al., 2005). This approach proved effective in reducing diagnostic costs by 30% (Schedvin et al., 2005).

Herrmann and Obeid proposed a two-step algorithm for the diagnosis of vitamin B₁₂ in adults that utilizes holo-TC and MMA as biomarkers (Herrmann and Obeid, 2013). Analysis of 1359 samples submitted to the laboratory for total vitamin B₁₂ assessment showed that patients exhibiting holo-TC values between 23 and 75 pmol/L and normal renal function should also be tested for MMA (Herrmann and Obeid, 2013). This guideline was widely recommended in Germany (Herrmann and Obeid, 2008) for the diagnosis of vitamin B₁₂ deficiency in risk groups including infants, unexplained anemia, unexplained neuropsychiatric symptoms, gastrointestinal conditions including stomatitis, anorexia and diarrhea, the elderly, vegetarians and individuals with gastrointestinal diseases such as ileum resection, chronic atrophic gastritis, Crohn's disease and *Helicobacter pylori* infection and individuals under

treatment with proton-pump inhibitors (Herrmann and Obeid, 2008; Hartmann et al., 2009; Koch, 2009; Heinzl, 2014). A cutoff of holo-TC of 50 pmol/L was set to discriminate between individuals unlikely to have vitamin B₁₂ deficiency (holo-TC > 50 pmol/L) vs. those potentially deficient in the micronutrient (holo-TC < 50 pmol/L) (Herrmann and Obeid, 2008). Patients with potential vitamin B₁₂ deficiency were first stratified by holo-TC levels as very low (holo-TC < 35 pmol/L) and low (holo-TC 36–50 pmol/L), and a second-line testing of MMA follows thereafter. Results from MMA lead to a three-block classification of patients, where (a) MMA < 271 nmol/L with holo-TC < 35 pmol/L represents a negative vitamin B₁₂ balance (insufficiency), (b) MMA < 271 nmol/L with holo-TC 36–50 pmol/L suggests the patient is unlikely to be vitamin B₁₂ deficient, and (c) a range of possible vitamin B₁₂ deficient patients is characterized by MMA > 271 nmol/L with holo-TC being very low or low (Herrmann and Obeid, 2008).

Berg and Shaw presented a cascade-testing algorithm that stratified patients first by total serum vitamin B₁₂ levels and second by MMA levels, using cutoffs of 118 pmol/L and 0.80 μmol/L, respectively (Berg and Shaw, 2013). The authors encouraged the sequential measurement of these two biomarkers prior to the implementation of vitamin B₁₂ therapy in patients.

Guidelines from the British Committee for Standards in Hematology suggested the use of total serum vitamin B₁₂ as the first-line test, with MMA as the second-line test (Devalia et al., 2014). For the reasons presented in the sections above, this approach would exclude a significant fraction of patients for which serum vitamin B₁₂ does not reflect cellular, genetic, and pharmacological disturbances that lead to functional vitamin B₁₂ deficiency. It was also recommended that individuals classified as having “subclinical deficiency” be provided with empirical therapy with oral CNCbl 50 μg daily for 4 weeks, and have their serum B₁₂ levels re-checked after 3 months (Devalia et al., 2014). Immediate medical attention was recommended for patients with symptoms of neuropathy.

Studies conducted by Palacios et al. on a cohort of 218 institutionalized elderly patients with median age 80 years old showed that an algorithm that combined biochemical, hematological, and morphological data proved more effective for the diagnosis of vitamin B₁₂ than the isolated markers (Palacios et al., 2013). The proposed algorithm combines erythrocyte and serum folate, holo-TC, and MMA, and excludes serum vitamin B₁₂ and tHcy measurements. The biomarkers selected in this algorithm permit the discrimination between isolated folate and vitamin B₁₂ deficiencies as well as the combined deficiency of both vitamins (Palacios et al., 2013).

Fedosov and colleagues developed a series of equations that combine two, three, or four biomarkers of vitamin B₁₂ status in adults. Age effects and folate status, a modifier of vitamin B₁₂ metabolism, are also considered (Fedosov et al., 2015). The combined indicator of vitamin B₁₂ status, cB₁₂, is defined as: $cB_{12} = \log_{10}(\text{holo-TC} \cdot B_{12}) / (\text{MMA} \cdot \text{tHcy}) - (\text{age factor})$ (Fedosov et al., 2015), and thus, it differs from the “if → then” structure of classic diagnostic algorithms. The combined indicator of vitamin B₁₂ status provides five distinct ranges of diagnostic value, which are summarized in **Table 1**.

TABLE 1 | Ranges of combined vitamin B₁₂ status, their equivalence to single cut-off values, and clinical interpretation.

Combined vitamin B ₁₂ status	Equivalence to single cut-points	Interpretation
Elevated B ₁₂ >1.5	B ₁₂ > 650 Holo-TC > 190 tHcy < 8.0 MMA < 0.11	The biological effects of high vitamin B ₁₂ are not fully understood
Adequate B ₁₂ -0.5 to 1.5	186 < B ₁₂ < 650 37 < holo-TC < 190 13.6 > tHcy > 8.0 0.35 < MMA < 0.11	Expected to support normal B ₁₂ -dependent functions
Low B ₁₂ -1.5 to -0.5	119 < B ₁₂ < 186 20 < holo-TC < 37 19.2 > tHcy > 13.6 0.84 < MMA < 0.35	Subclinical deficiency. No hematological changes, subtle neurological impairment
Possible B ₁₂ deficiency -2.5 to -1.5	116 < B ₁₂ < 119 8.4 < holo-TC < 20 51 > tHcy > 19.2 1.7 < MMA < 0.84	Potential manifestations of vitamin B ₁₂ deficiency
Probable B ₁₂ deficiency < -2.5	B ₁₂ < 116 holo-TC < 8.4 tHcy > 51 MMA > 1.7	Clinical manifestations of vitamin B ₁₂ deficiency

Units: B₁₂ and holo-TC are expressed in pmol/L, and tHcy and MMA in μmol/L. Table adapted from Fedosov et al. (2015).

This classification considers both extremes of vitamin B₁₂ diagnostics, i.e., very low and very high vitamin B₁₂ status. The pathophysiological implications of high vitamin B₁₂ status are poorly understood, but its occurrence has been reviewed in the literature (Arendt and Nexø, 2013). The cB₁₂ quotient has been successfully adopted to investigate the vitamin B₁₂ status of a cohort of healthy Swiss elders (Risch et al., 2015). Results from this study suggest that increased levels of MMA and Hcy in seniors are brought about by a reduced renal function due to aging rather than by an underlying vitamin B₁₂ insufficiency (Risch et al., 2015). Nonetheless, the study identified a clear trend of more prevalent metabolic vitamin B₁₂ deficiency (measured as cB₁₂) with increasing age (Risch et al., 2015). Another study showed that the cB₁₂ indicator was useful not only to identify vitamin B₁₂ deficiency, but also to find interactions with folate status (Brito et al., 2016). Further, the cB₁₂ indicator was effective in identifying vitamin B₁₂ in cancer patients who exhibit normal serum vitamin B₁₂, but increased levels of MMA and Hcy (Vashi et al., 2016). In this study, the cB₁₂ quotient helped to establish that MMA is the most sensitive marker of vitamin B₁₂ in cancer patients, and that total serum B₁₂ has very little diagnostic value (Vashi et al., 2016). None of the studies included a decrease in MMA or tHcy upon B₁₂ administration as a potential marker in the evaluation of potential B₁₂ deficiency.

VITAMIN B₁₂ DEFICIENCY IN INFANTS

Infant cobalamin status at birth depends on maternal cobalamin stores during pregnancy, placental function, gestational age,

and birth weight. There is a complex cobalamin metabolism in the placental-fetal compartment, strictly regulating the cobalamin transfer to the fetus (Porck et al., 1983; Miller et al., 1993; Perez-D'gregorio and Miller, 1998; Obeid et al., 2006). Cobalamin and holo-TC levels in the placenta, cord blood, and newborn serum correlate with maternal levels, but are 2–3 fold higher (Luhby et al., 1958; Baker et al., 1975; Giugliani et al., 1985; Frery et al., 1992; Obeid et al., 2006), providing the newborn with a liver store of about 25 μg cobalamin assumed to be sufficient for the first year of life (McPhee et al., 1988).

A wide range of cobalamin levels, varying from 86 to 939 pmol/L (median of 264 pmol/L) (Minet et al., 2000), have been reported for neonates during the first month of life. Maternal cobalamin deficiency, prematurity, and low birth weight are all associated with lower fetal cobalamin stores and an increased risk of deficiency, particularly if the infant is exclusively breastfed for more than 4 months before animal food is introduced (Dror and Allen, 2008; Torsvik et al., 2015). In mainly breastfed infants, the cobalamin level remains at cord blood levels for 5–7 days, then drops sharply, followed by a slow decline, reaching nadir levels at 6–7 months (Minet et al., 2000; Fokkema et al., 2002; Monsen et al., 2003). The decrease in serum cobalamin is accompanied by an increase in the metabolic markers plasma tHcy and MMA (Minet et al., 2000; Bjørke Monsen et al., 2001). This metabolic profile, indicative of cobalamin deficiency (Schneede et al., 1994), is associated with functional motor impairment in infants (Torsvik et al., 2013, 2015). Randomized intervention studies with one-time injection of 400 μg hydroxycobalamin are reported to improve the metabolic pattern and gross motor

development compared with infants receiving placebo (Torsvik et al., 2013, 2015).

Reported cobalamin levels in human breast milk vary from 150 to 700 pmol/L (Specker et al., 1990a; Ford et al., 1996; Greibe et al., 2013a; Duggan et al., 2014), depending on the assay used (Black et al., 1994; Lildballe et al., 2009), maternal cobalamin levels and the stage of lactation, as cobalamin levels in breast milk falls progressively during the first months (Greibe et al., 2013a). The cobalamin content of breast milk appears to be lowest at 4 months after birth, and this coincides with a low cobalamin status in the infant (Greibe et al., 2013a). Gradually decreasing cobalamin status with increasing time of exclusively breastfeeding has also been reported in infants with a subnormal birthweight (2–3 kg) during the first 6 months of life (Torsvik et al., 2015). Most commercially prepared infant formulas are enriched with cobalamin up to concentrations of 800–1200 pmol/L, well above that of human milk (Ford et al., 1996), and higher cobalamin and lower tHcy and MMA levels are seen in formula-fed infants (Specker et al., 1990b; Minet et al., 2000; Fokkema et al., 2002; Hay et al., 2008).

After introduction of animal food, the cobalamin level increases and peaks at 3–7 years and then decreases, median plasma tHcy decreases and remains low until 7 years when it starts increasing, whereas median plasma MMA decreases after 12 months and remains low throughout childhood (Monsen et al., 2003). tHcy is considered the best metabolic marker of cobalamin status in infants and toddlers and a plasma tHcy cut-off level of 6.5 μmol/L has been suggested for defining cobalamin deficiency in this age-group (Bjørke-Monsen et al., 2008). This represents the 97.5 percentile in 4 months old infants given a single intramuscular dose of 400 μg hydroxocobalamin at 6 weeks, rendering them to be cobalamin optimized (Bjørke-Monsen et al., 2008). In addition, administration of folic acid in newborns did not reduce tHcy (Hogeveen et al., 2010). In older children and adults, tHcy is mainly a folate marker, while MMA is considered a good marker for cobalamin status (Bjørke Monsen and Ueland, 2003; Monsen et al., 2003).

CHALLENGES IN THE DIAGNOSIS OF VITAMIN B₁₂ DEFICIENCY

Subclinical B₁₂ Deficiency Is Asymptomatic

The diagnosis and management of subclinical vitamin B₁₂ deficiency, which is defined as a total serum B₁₂ concentration of 150–249 pmol/L (Carmel, 2012, 2013) is a matter of great interest, due to its much higher prevalence (up to 40% of the population in western countries) compared to clinical deficiency (Carmel, 2012, 2013). The etiology of subclinical vitamin B₁₂ is unknown (Carmel, 2013). The condition manifests without overt clinical findings, with marginal or no elevation in tHcy and MMA and is typically of non-malabsorptive causes (Carmel, 2013). Subclinical B₁₂ deficiency rarely evolves into clinical deficiency and the need for treatment with B₁₂ has not been fully established in spite of its much higher frequency compared to clinical B₁₂ deficiency (Carmel, 1996, 1998, 1999, 2011, 2013). A study with a population of asymptomatic B₁₂-deficient elderly Chileans showed that patients displayed improved function of myelinated


peripheral nerves after vitamin B₁₂ treatment and a positive association with folate status (Brito et al., 2016).

Functional B₁₂ Deficiency: Serum Markers vs. Cellular Status of Vitamin B₁₂

A number of studies point to the lack of correlation between serum and cellular levels of vitamin B₁₂ (Carmel, 2000; Solomon, 2005; Devalia et al., 2014; Lysne et al., 2016), and this is particularly important in the case of inborn errors of cobalamin metabolism whereby serum levels of the micronutrient are within the normal range (Watkins and Rosenblatt, 2013). In this regard, serum vitamin B₁₂ and holo-TC should be avoided as sole markers of B₁₂ deficiency in neonatal screening. Time-consuming metabolic studies to uncover genetic complementation or lack of function continue to be utilized in a very limited number of metabolic centers worldwide (Figure 3). In newborn screenings where biochemical markers are indicative of vitamin B₁₂ deficiency, the diagnosis of inborn errors of vitamin B₁₂ metabolism is performed via functional studies on cultured fibroblasts isolated from skin biopsies (Watkins and Rosenblatt, 2013) or via molecular genetic analysis of putative genes. Functional studies include [¹⁴C]-propionate or [¹⁴C]-N⁵-methyl-tetrahydrofolate incorporation into cellular macromolecules, to assess the activities of MCM and MS, respectively, and biosynthesis of MeCbl and AdoCbl upon metabolic labeling with holo-TC made from apo-TC and commercially available [⁵⁷Co]-vitamin B₁₂ (Watkins and Rosenblatt, 2013). Decreased uptake of [⁵⁷Co]-vitamin B₁₂ is indicative of impaired receptor-mediated endocytosis of holo-TC by the transcobalamin receptor. Accumulation of [⁵⁷Co]-vitamin B₁₂ in the lysosome suggests a dysfunctional cblF or cblJ protein unable to mediate exit of B₁₂ from the organelle (Figure 1). Isolated or combined disruption of MeCbl and AdoCbl levels indicates failures in intracellular processing (cblC, cblX), trafficking (cblD), and/or coenzyme biosynthesis and utilization (cblA, cblB, cblG, cblE, mut). When results from [¹⁴C]-propionate or [¹⁴C]-N⁵-methyl-tetrahydrofolate incorporation suggest abnormal vitamin B₁₂ metabolism, somatic cell complementation analysis usually follows (Watkins and Rosenblatt, 2013). Cells from patients are fused with cells from other patients with confirmed mutations using polyethylenglycol and the [¹⁴C]-propionate or [¹⁴C]-N⁵-methyl-tetrahydrofolate incorporation studies are repeated to interrogate complementation of function. If the incorporation is corrected with respect to control cell lines, then the two cell lines belong to different complementation groups. In contrast, lower than normal [¹⁴C]-propionate or [¹⁴C]-N⁵-methyl-tetrahydrofolate incorporation after fusion of cell lines with polyethylenglycol confirms that the two patients possess the same genetic defect (Watkins and Rosenblatt, 2013). Nowadays, the vast majority of genes whose mutation lead to functional vitamin B₁₂ deficiency have been identified, and therefore, sequencing of these genes or next generation sequencing permits unequivocal diagnosis (Pupavac et al., 2016).

Combined B₁₂ and Iron Deficiency

Iron deficiency is a condition that could lead to masking of megaloblastic anemia caused by vitamin B₁₂ and folate



deficiencies (Remacha et al., 2013). The combined deficiency of iron and vitamin B₁₂ deficiency is more prominent in individuals aged 60 and older. In general, albeit not always, iron deficiency leads to microcytosis whereas vitamin B₁₂ and folate deficiencies result in macrocytosis (Green, 2012). An algorithm to distinguish between these two large classes of anemia based on a decreased in RBC count, hematocrit and hemoglobin levels has been described (Green, 2012). In addition, an algorithm that introduces age and tHcy levels has been developed to discriminate iron deficiency anemia vs. iron and vitamin B₁₂ combined anemia (Remacha et al., 2013).

VITAMIN B₁₂ STATUS IN SPECIAL POPULATIONS

The Elderly

Despite an apparent sufficient intake, vitamin B₁₂ deficiency is common among the elderly, and the prevalence is shown to increase with age (Allen, 2009; Miles et al., 2015). This is most likely not a physiological change due to aging *per se*, but a consequence of the elderly being more prone to gastric dysfunction, with variable degrees of gastric atrophy and achlorhydria interfering with the absorption of vitamin B₁₂ from

foods (Carmel, 1997). Most cases of low vitamin B₁₂ among the elderly are accompanied by metabolic changes related to deficiency (Carmel, 1997). However, there is limited evidence from observational research linking this to clinical symptoms of deficiency (Miles et al., 2015). Because these metabolic changes usually respond to treatment with oral vitamin B₁₂, low serum concentrations of vitamin B₁₂ in the absence of clinical symptoms should be regarded as a state of subclinical deficiency. An increasing folate status due to folic acid fortification and/or folic acid supplementation has been demonstrated to accelerate and worsen both the metabolic and the clinical consequences of B₁₂ deficiency (Morris et al., 2007; Selhub et al., 2007). Low vitamin B₁₂ levels among the elderly should be considered grounds for concern in countries with mandatory folic acid fortification.

Bariatric Surgery and Gastrointestinal Disorders

The absorption of vitamin B₁₂ is largely dependent on a healthy gastrointestinal tract, including (i) the production of intrinsic factor by parietal cells in the stomach, (ii) the dissociation of B₁₂ from haptocorrin and binding to intrinsic factor in the neutral environment of the duodenum, and (iii) the uptake of vitamin B₁₂ in the ileum. Pernicious anemia, an autoimmune disorder against gastric parietal cells, and bariatric surgery put the patient at risk of developing vitamin B₁₂ deficiency by limiting intestinal absorption and/or by reduction of food intake. In addition to reducing intake of the vitamin itself, bariatric surgery may diminish the secretion of intrinsic factor in the stomach, which is normally produced and released in response to food intake (Marcuard et al., 1989). Finally, limited contact with the pancreatic juice due to a shorter common intestinal tract after surgery may hinder the release from haptocorrin, limiting the intestinal uptake. High prevalence of B₁₂ deficiency has frequently been reported in subjects undergoing bariatric surgery (Sumner et al., 1996; Shah et al., 2006), and low levels of serum cobalamin is reported to be more indicative of true deficiency in bariatric surgery patients compared to healthy controls (Sumner et al., 1996). The malabsorptive procedures have been shown to yield higher risk of B₁₂ deficiency compared to the restrictive procedures (Kwon et al., 2014). In studies where the patients received post-operative intramuscular supplementation of vitamin B₁₂, however, no increased risk of becoming deficient is observed (Kwon et al., 2014). In a study of vitamin B₁₂ status 5 years after surgery, patients who received intramuscular injections of vitamin B₁₂ increased their serum concentration, while the concentration among those not receiving injections decreased (Aaseth et al., 2015). Patients who underwent bariatric surgery would benefit from life-long preventive and maintenance supplementation with vitamin B₁₂. More broadly, gastrointestinal disorders that affect the small intestine (for example, ileal resection) could increase the risk of B₁₂ deficiency through malabsorption (Battat et al., 2014). High prevalence of vitamin B₁₂ deficiency has been reported among untreated celiac disease patients (Theethira et al., 2014). Hence, patients newly diagnosed with celiac disease should be screened for B₁₂ deficiency. Vitamin B₁₂ deficiency is also frequently associated with chronic gastritis, which is most often a consequence of *H. pylori* infection (Varbanova et al., 2014).

Neurological Disorders

The consequences of vitamin B₁₂ deficiency at the onset and progression of neurological impairments are well established (Kumar, 2014). In contrast, the causative role of vitamin B₁₂ deficiency in neurological disorders such as Parkinson's, Alzheimer's, and others is controversial. A review of 43 studies worldwide showed that low serum vitamin B₁₂ levels correlate with increased neurodegenerative disease and cognitive impairment (Moore et al., 2012). While a small subset of dementias examined in some of these studies responded favorably to vitamin B₁₂ supplementation, no benefit was observed in patients with an established, pre-existing deficiency of vitamin B₁₂ (Moore et al., 2012). One explanation may be that at least some of the neurological consequences of vitamin B₁₂ deficiency are irreversible. Another possibility is that the relationship between B₁₂ status and neurological disorders is not causal. A comprehensive analysis of studies performed from 2002 to 2012 examined tHcy levels with respect to dementia and cognitive decline (Health Quality Ontario, 2013). The results were controversial based on sample size and study design. Although the authors described an association between elevated tHcy and the onset of dementia, treatment with vitamin B₁₂ did not improve cognitive function (Health Quality Ontario, 2013). On the other hand, a slower rate of brain atrophy was noted in patients with mild cognitive impairment who have received treatment with vitamin B₁₂ (effective with both oral and parenteral administration) and folate (Health Quality Ontario, 2013). Elevated tHcy and MMA were identified in a small cohort of patients with Parkinson's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis compared to healthy subjects (Levin et al., 2010). In all cases, patients with these neurological diseases presented serum vitamin B₁₂ and folate comparable to that of healthy controls (Levin et al., 2010), suggesting a functional vitamin deficiency. It is unclear whether increased tHcy and MMA contribute to the onset and progression of neurological disease and whether supplementation with cobalamin, in spite of normal serum levels of the micronutrient, may help to reduce these neurotoxic metabolites. It has also been suggested that treatment of Parkinson's and other neurological diseases with levodopa results in elevation of tHcy through S-adenosylmethionine-dependent methylation of levodopa by catechol O-methyl-transferase (Muller, 2009; Muller et al., 2013). The authors proposed that treatment of these diseases with a combination of levodopa and an inhibitor of O-methyl-transferase may prevent tHcy elevation and oxidative stress (Muller, 2009). Advanced-stage patients with Parkinson's disease typically receive continuous intraduodenal infusion of levodopa or carbidopa intestinal gel (Muller et al., 2013). These patients develop peripheral neuropathies thought to arise from transient deficiency of vitamins B₆ and B₁₂ as judged by a favorable response to concomitant supplementation with these micronutrients (Muller et al., 2013). A study performed with 1354 elder Australian subjects showed an association between low vitamin B₁₂ levels and cognitive impairments that was enhanced in the presence of high folate intake (Moore et al., 2014). Furthermore, the study identified that subjects exhibiting normal serum vitamin B₁₂ levels in the presence of high erythrocyte folate were also more likely to develop cognitive

impairment (Moore et al., 2014). Unfortunately, this study did not determine metabolic markers of vitamin B₁₂ deficiency such as MMA or tHcy. Altogether, available data suggests that preventing a deficiency of vitamin B₁₂ may afford protection from neurological deterioration, and that some but not all cognitive impairments respond to therapy with vitamin B₁₂. In terms of causation, the contribution of insufficient vitamin B₁₂ metabolism to the onset and progression of unrelated disorders such as Parkinson's and Alzheimer's diseases and other dementias awaits the implementation of large population clinical trials.

Autoimmune Lymphoproliferative Syndrome

ALPS is a genetic disorder leading to defective lymphocyte apoptosis (Oliveira, 2013; Shah et al., 2014). This results in an accumulation of lymphocytes, splenomegaly, multilineage cytopenias, lymphadenopathy, hepatomegaly, and an increased risk of B-cell lymphoma. The disease is accompanied nearly always by autoimmune manifestations (Jackson et al., 1999; Oliveira et al., 2010). Most ALPS patients are affected by heterozygous germline mutations in the Fas cell surface death receptor gene (*FAS*) via autosomal dominant inheritance (Jackson et al., 1999; Holzelova et al., 2004; Oliveira et al., 2010). Somatic mutations in *FAS* have also been described albeit less frequently (Jackson et al., 1999; Holzelova et al., 2004; Oliveira et al., 2010). *FAS* is a member of the tumor necrosis factor receptor family (*FAS/CD95/APO-1/TNFRSF6*) and it is highly expressed in activated B and T cells (Nagata and Golstein, 1995). *FAS-FAS* ligand recognition in activated T lymphocytes leads to the activation of the caspase cascade and cellular apoptosis (Nagata and Golstein, 1995). This apoptotic pathway is important for the down-regulation of the immune response, and its disturbance leads to buildup of proliferating lymphocytes resulting in lymphoid hyperplasia and autoimmunity (Rieux-Laucat et al., 2003). Revised diagnostic criteria and classification for the ALPS syndrome were established in 2009 at a US National Institutes of Health International Workshop. Required criteria for ALPS included the presence of lymphadenopathy and/or splenomegaly and elevated TCR $\alpha\beta^+$ -DNT cells. Accessory criteria for ALPS were subdivided into primary (abnormal lymphocyte apoptosis assay and presence of pathogenic mutations in genes of the *FAS* pathway) and secondary criteria, which included characteristic histopathology, the combined presence of autoimmune cytopenia, polyclonal hypergammaglobulinemia, an ALPS-compatible family history, and the presence of elevated biomarkers, such as interleukin-10, interleukin-18, soluble *FAS* ligand, and vitamin B₁₂ (Oliveira et al., 2010). These biomarkers are included in the diagnostic criteria because they can predict both germline and somatic *FAS* mutations with a post-test probability from 85 to 97% (87% for vitamin B₁₂) and because they are accessible to facilities without the ability to do genetic analysis or functional assays (Teachey et al., 2005; Magerus-Chatinet et al., 2009; Caminha et al., 2010; Seif et al., 2010). Very highly elevated median serum vitamin B₁₂ in ALPS Ia and Ia-s (1667 pmol/L; 1220 pmol/L) compared with mutation-negative relatives (350 pmol/L; $P < 0.0001$) and healthy mutation-positive relatives (421 pmol/L; $P < 0.0001$) have been reported (Caminha et al., 2010). In particular, serum

vitamin B₁₂ median levels in ALPS III and ALPS-Phenotype were substantially elevated (560 and 696 pmol/L) (Caminha et al., 2010). Another group observed significantly higher mean serum vitamin B₁₂ concentrations (3900 pmol/L; controls: 274 pmol/L; $p < 0.0001$) and significantly higher mean holo-haptocorrin (holo-HC) concentrations (3810 pmol/L; controls: 194 pmol/L; $p < 0.0001$) in the presence of normal holo-TC concentrations (Bowen et al., 2012). The abnormally high levels of circulating vitamin B₁₂ found in ALPS patients has been ascribed to high expression of HC by lymphocytes isolated from ALPS patients, a characteristic not observed in lymphocytes isolated from healthy control subjects (Bowen et al., 2012). Thus, it would appear that HC expression is upregulated in ALPS. In the Bowen et al. study, the metabolic markers of vitamin B₁₂ status (tHcy and MMA) in ALPS patients were investigated and no differences with respect to healthy controls were found (Bowen et al., 2012). This is consistent with the fact that high serum holo-HC does not impair holo-TC uptake by the cellular TCbIR (Quadros et al., 2009, 2010; Jiang et al., 2013; Quadros and Sequeira, 2013) and the downstream intracellular utilization of the micronutrient (Hannibal et al., 2009, 2013). It remains to be determined whether excess serum vitamin B₁₂ found in ALPS patients derives from clearance of liver storages or simply by increased dietary assimilation.

Vegetarians and Vegans

Although a properly planned vegetarian diet is regarded as nutritionally adequate and healthy, unsupplemented populations who actively avoid food of animal origin are at high risk of insufficient dietary intake of vitamin B₁₂. The amount of B₁₂ in vegetarian diets depends on the extent of inclusion of animal products or the use of dietary supplements. Supplementation is recommended to those completely avoiding animal products (strict vegans). Compared to meat eaters, both vegetarians and particularly vegans have a lower intake of vitamin B₁₂ (Davey et al., 2003; Rizzo et al., 2013; Kristensen et al., 2015; Schupbach et al., 2015). This is also reflected by lower serum concentrations (Gilsing et al., 2010), and vitamin B₁₂ deficiency is shown to be common following all types of vegetarian diets (Pawlak et al., 2013, 2014). However, in a study comparing micronutrient status in omnivores, vegetarians and vegans from Switzerland, a low vitamin B₁₂ intake among vegans was not accompanied by low serum concentrations of the micronutrient (Schupbach et al., 2015). This was attributed to widespread use of B₁₂ supplements, which adheres to dietary recommendations for this subpopulation (Pawlak et al., 2014). Infants of vegan mothers not taking supplements are also at increased risk of becoming vitamin B₁₂ deficient, especially so when exclusively breastfed (Dror and Allen, 2008). This is due both to small hepatic stores and low intake through the breast milk, both a result of poor maternal vitamin B₁₂ status. In light of these findings, it is advised that vegetarians and vegans monitor their serum vitamin B₁₂ levels and at least one metabolic marker (tHcy or MMA), or consider taking a B₁₂ supplement as part of their dietary plan.

Medication Affecting Vitamin B₁₂ Status

Besides factors influencing the intake and absorption of vitamin B₁₂, some medications have been shown to interfere with vitamin

B₁₂ absorption or metabolism, potentially putting certain patient groups at risk of developing vitamin B₁₂ deficiency. Metformin (Glucophage) is regarded a first-line drug in the treatment of type 2 diabetes mellitus. However, it has been shown that treatment with metformin is associated with a decrease in serum vitamin B₁₂ concentrations, which worsens with increasing dose and length of treatment (Ting et al., 2006; de Jager et al., 2010; Liu et al., 2014). The association has been suggested to be due to interference with the calcium dependent intestinal uptake of the vitamin B₁₂-intrinsic factor complex (Bauman et al., 2000). However, although serum B₁₂ is reduced, metformin treatment has been associated with reduction in plasma MMA and indications of improved intracellular B₁₂ status in diabetics (Obeid et al., 2013). Hence, a vitamin B₁₂ resistance phenomenon was suggested in diabetics, and metformin treatment seemed to improve the intracellular vitamin B₁₂ metabolism, contrary to previous beliefs. Two studies found that patients treated with metformin had reduced levels of both serum vitamin B₁₂ and haptocorrin, but treatment was without effect on the levels of holo-TC, the bioactive form of vitamin B₁₂ that is distributed systemically to all cells in the body (Leung et al., 2010; Greibe et al., 2013c). Another study showed that treatment of rats with metformin increased hepatic accumulation of vitamin B₁₂ (Greibe et al., 2013b). This suggests that metformin may alter the homeostasis and tissue distribution of vitamin B₁₂, the consequences of which remain to be investigated. Because not all cases of low serum vitamin B₁₂ imply deficiency, and normal and high serum levels of vitamin B₁₂ are likewise observed in patients with severe functional vitamin B₁₂ deficiency, concern has been raised regarding the interpretation of the effects of metformin on vitamin B₁₂ status (Obeid, 2014). In terms of prevention, diabetics receiving metformin should be regarded at increased risk, and routine screening and supplementation if necessary, should be recommended (Valdes-Ramos et al., 2015).

Proton pump inhibitors or other medications that suppress acid production in the stomach are frequently associated with reduced serum vitamin B₁₂ concentrations (Abraham, 2012). This is due to the acidic environment in the stomach being essential for the release of protein-bound vitamin B₁₂, as well as initial binding to haptocorrin (Stabler, 2012). While serum vitamin B₁₂ is reduced, it usually stays within the normal range (Sheen and Triadafilopoulos, 2011). Hence, the risk of developing overt deficiency due to use of proton pump inhibitors may be low, but it has been suggested that the risk is higher among elderly and malnourished patients receiving long-term treatment (Sheen and Triadafilopoulos, 2011).

Nitrous oxide, an inhalant used for surgical and dental anesthesia and also as a recreational drug (van Amsterdam et al., 2015), directly affects vitamin B₁₂ metabolism by irreversibly oxidizing the cobalt atom in B₁₂-dependent MS (Guttormsen et al., 1994; Torri, 2010). When subjects with borderline vitamin B₁₂ deficiency are treated with nitrous oxide, rapid onset of neurological symptoms has been reported post treatment (Singer et al., 2008). Patients who are candidates for interventions with nitrous oxide anesthesia may benefit from pre-operative supplementation with vitamin B₁₂.

GENETIC DETERMINANTS OF VITAMIN B₁₂ STATUS

Aside from inborn errors of metabolism affecting the intracellular pathways of vitamin B₁₂ trafficking and assimilation (for excellent reviews on the topic see Froese and Gravel, 2010; Watkins and Rosenblatt, 2011), mutations in the transcobalamin gene (TCN2) (Keller et al., 2016), high levels of the soluble transcobalamin receptor (sCD320) Hoffmann-Lucke et al., 2013, and polymorphisms in 3-hydroxybutyryl-CoA hydrolase (HIBCH) (Molloy et al., 2016) also affect the serum markers of vitamin B₁₂ status. Mutations in the TCN2 gene can lead to false low levels of circulating holo-TC without effect on other biomarkers of vitamin B₁₂ status (Keller et al., 2016). Increased levels of a heavier variant of the sCD320 led to elevated holo-TC and vitamin B₁₂ in serum, though the reasons for such variations are currently unknown (Hoffmann-Lucke et al., 2013). The larger apparent molecular weight of sCD320 could be due to altered glycation or formation of higher order oligomers of the sCD320 (Hoffmann-Lucke et al., 2013). A genome-wide analysis in 2210 healthy Irish adults identified strong associations between plasma MMA with SNPs in acylCo-A synthetase (ACSF3) and HIBCH, with these loci accounting for 12% of the variance in MMA concentration (Molloy et al., 2016). HIBCH catalyzes a unique step in the degradation of valine, converting 3-hydroxyisobutyric acid-CoA to 3-hydroxyisobutyric acid. The presence of polymorphisms in HIBCH represents an independent determinant of serum MMA concentrations. The molecular mechanism by which polymorphic variants of HIBCH lead to elevated MMA remain to be investigated (Molloy et al., 2016). Transient elevation of MMA has also been documented in patients with mutations in methylmalonate semialdehyde dehydrogenase (Marcadier et al., 2013), and in ACSF3, which possesses malonyl-CoA and methylmalonyl-CoA activity (Alfares et al., 2011; Sloan et al., 2011). Mutations in mitochondrial succinate-CoA ligase (SUCLG1) also lead to elevated MMA (Valayannopoulos et al., 2010).

Mutations that impair the endocytic and lysosomal pathways independently of vitamin B₁₂ metabolism also lead to transient deficiency of the micronutrient, with elevation of tHcy and MMA (Stockler et al., 2014; Dutchak et al., 2015; Zhao et al., 2015). These include abnormal lysosome acidification in a patient with Alzheimer's disease (Zhao et al., 2015), impaired endocytosis due to a mutation in the rabenosyn-5 gene (Stockler et al., 2014; Zhao et al., 2015), and disrupted lysosomal acidification and gene expression in a knock-out mouse model of mTOR inhibitor NPRL2 (Dutchak et al., 2015). This pathway is thought to cause a defective processing of holo-TC in the lysosome (Dutchak et al., 2015).

Upregulation of the expression of hepatic peroxisome proliferator activated receptor alpha (PPAR alpha), has been shown to elevate plasma MMA in male Wistar rats fed a normal high fat diet in the presence of PPAR alpha agonist tetradecylthioacetic acid (TTA) (Lysne et al., 2016). Because the amount of receptor is a limiting factor for PPAR alpha activity,

and the amount of PPAR alpha protein strongly correlates with its level of mRNA expression (Lemberger et al., 1996), differential expression of PPAR alpha induced by diet, stress and other factors may represent another vitamin B₁₂-independent determinant of plasma MMA.

Overall, the finding that mutations and polymorphisms in genes peripheral or unrelated to intracellular vitamin B₁₂ pathways affect its marker metabolites, substantiates the need for the combined analysis of at least two biomarkers for the accurate assessment of vitamin B₁₂ status.

CONCLUDING REMARKS

The diagnosis of vitamin B₁₂ deficiency both in children and adults requires the use of at least two biomarkers. Among the biomarkers currently available for diagnostic purposes, total serum vitamin B₁₂ is equivocal for the identification of functional deficiencies, such as those caused by inborn errors of metabolism. The use of holo-TC to determine vitamin B₁₂ status is advantageous in that it reflects the biologically active pool of vitamin B₁₂ in serum, but its homeostasis is poorly understood. This is illustrated by the abnormal levels of holo-TC observed under various unrelated disease states and in individuals possessing otherwise normal total serum vitamin B₁₂. tHcy is particularly useful as a marker of vitamin B₁₂ status in

the neonate, but its reliability and specificity are equivocal in adulthood because it is influenced by many factors such as folate status. Methylmalonic acid continues to be the most sensitive and specific marker for vitamin B₁₂ status in individuals of all ages with normal renal function. The use of acylcarnitines can be considered ancillary to diagnosis, but certainly not a first-line test. One major challenge lies in identifying early markers of low vitamin B₁₂ status for the timely diagnosis of the clinically and biochemically silent subclinical vitamin B₁₂ deficiency. Likewise, the consequences of insufficient vitamin B₁₂ levels in special populations such as the elderly, vegetarians and vegans, infants, and pregnant women suffer from poor awareness by both patients and clinicians. The finding that low vitamin B₁₂ status is associated with more prominent metabolic markers of vitamin B₁₂ deficiency in the presence of high folic acid concentrations (Miller et al., 2009) points to the importance of nutrient-nutrient interactions, which have only been considered over the past decade and is of particular relevance to countries with ongoing folic acid fortification of foods.

AUTHOR CONTRIBUTIONS

All authors listed, have made substantial, direct and intellectual contribution to the work, and approved it for publication.

REFERENCES

- Aaseth, E., Fagerland, M. W., Aas, A. M., Hewitt, S., Risstad, H., Kristinsson, J., et al. (2015). Vitamin concentrations 5 years after gastric bypass. *Eur. J. Clin. Nutr.* 69, 1249–1255. doi: 10.1038/ejcn.2015.82
- Abraham, N. S. (2012). Proton pump inhibitors: potential adverse effects. *Curr. Opin. Gastroenterol.* 28, 615–620. doi: 10.1097/MOG.0b013e328358d5b9
- Alfares, A., Nunez, L. D., Al-Thihli, K., Mitchell, J., Melancon, S., Anastasio, N., et al. (2011). Combined malonic and methylmalonic aciduria: exome sequencing reveals mutations in the ACSF3 gene in patients with a non-classic phenotype. *J. Med. Genet.* 48, 602–605. doi: 10.1136/jmedgenet-2011-100230
- Allen, L. H. (2009). How common is vitamin B-12 deficiency? *Am. J. Clin. Nutr.* 89, 693S–696S. doi: 10.3945/ajcn.2008.26947A
- Antony, A. C. (2001). Prevalence of cobalamin (vitamin B-12) and folate deficiency in India—audi alteram partem. *Am. J. Clin. Nutr.* 74, 157–159.
- Arendt, J. F., and Nexo, E. (2013). Unexpected high plasma cobalamin: proposal for a diagnostic strategy. *Clin. Chem. Lab. Med.* 51, 489–496. doi: 10.1515/cclm-2012-0545
- Arendt, J. F., Farkas, D. K., Pedersen, L., Nexo, E., and Sorensen, H. T. (2016). Elevated plasma vitamin B₁₂ levels and cancer prognosis: A population-based cohort study. *Cancer Epidemiol.* 40, 158–165. doi: 10.1016/j.canep.2015.12.007
- Aroda, V. R., Edelstein, S. L., Goldberg, R. B., Knowler, W. C., Marcovina, S. M., Orchard, T. J., et al. (2016). Long-term metformin use and Vitamin B₁₂ deficiency in the diabetes prevention program outcomes study. *J. Clin. Endocrinol. Metab.* 101, 1754–1761. doi: 10.1210/jc.2015-3754
- Baker, H., Frank, O., Thomson, A. D., Langer, A., Munves, E. D., De Angelis, B., et al. (1975). Vitamin profile of 174 mothers and newborns at parturition. *Am. J. Clin. Nutr.* 28, 59–65.
- Battat, R., Kopylov, U., Szilagyi, A., Saxena, A., Rosenblatt, D. S., Warner, M., et al. (2014). Vitamin B₁₂ deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management. *Inflamm. Bowel Dis.* 20, 1120–1128. doi: 10.1097/mib.0000000000000204
- Bauman, W. A., Shaw, S., Jayatilleke, E., Spungen, A. M., and Herbert, V. (2000). Increased intake of calcium reverses vitamin B₁₂ malabsorption induced by metformin. *Diabetes Care* 23, 1227–1231. doi: 10.2337/diacare.23.9.1227
- Baumgartner, M. R., and Fowler, B. (2014). *Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases*. Heidelberg: Springer-Verlag Berlin Heidelberg.
- Berg, R. L., and Shaw, G. R. (2013). Laboratory evaluation for vitamin B₁₂ deficiency: the case for cascade testing. *Clin. Med. Res.* 11, 7–15. doi: 10.3121/cm.2012.1112
- Bjørke Mønsen, A. L., and Ueland, P. M. (2003). Homocysteine and methylmalonic acid in diagnosis and risk assessment from infancy to adolescence. *Am. J. Clin. Nutr.* 78, 7–21.
- Bjørke Mønsen, A. L., Ueland, P. M., Vollset, S. E., Guttormsen, A. B., Markestad, T., Solheim, E., et al. (2001). Determinants of cobalamin status in newborns. *Pediatrics* 108, 624–630. doi: 10.1542/peds.108.3.624
- Bjørke-Monsen, A. L., Torsvik, I., Sætran, H., Markestad, T., and Ueland, P. M. (2008). Common metabolic profile in infants indicating impaired cobalamin status responds to cobalamin supplementation. *Pediatrics* 122, 83–91. doi: 10.1542/peds.2007-2716
- Black, A. K., Allen, L. H., Pelto, G. H., De Mata, M. P., and Chavez, A. (1994). Iron, vitamin B-12 and folate status in Mexico: associated factors in men and women and during pregnancy and lactation. *J. Nutr.* 124, 1179–1188.
- Bowen, R. A., Dowdell, K. C., Dale, J. K., Drake, S. K., Fleisher, T. A., Hortin, G. L., et al. (2012). Elevated vitamin B(1)(2) levels in autoimmune lymphoproliferative syndrome attributable to elevated haptocorrin in lymphocytes. *Clin. Biochem.* 45, 490–492. doi: 10.1016/j.clinbiochem.2012.01.016
- Brito, A., Verdugo, R., Hertrampf, E., Miller, J. W., Green, R., Fedosov, S. N., et al. (2016). Vitamin B-12 treatment of asymptomatic, deficient, elderly Chileans improves conductivity in myelinated peripheral nerves, but high serum folate impairs vitamin B-12 status response assessed by the combined indicator of vitamin B-12 status. *Am. J. Clin. Nutr.* 103, 250–257. doi: 10.3945/ajcn.115.116509

- Caminha, I., Fleisher, T. A., Hornung, R. L., Dale, J. K., Niemela, J. E., Price, S., et al. (2010). Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. *J. Allergy Clin. Immunol.* 125, 946–949. doi: 10.1016/j.jaci.2009.12.983
- Carmel, R. (1996). Subtle cobalamin deficiency. *Ann. Intern. Med.* 124, 338–340. doi: 10.7326/0003-4819-124-3-19960210-00010
- Carmel, R. (1997). Cobalamin, the stomach, and aging. *Am. J. Clin. Nutr.* 66, 750–759.
- Carmel, R. (1998). Mild cobalamin deficiency. *West. J. Med.* 168, 522–523.
- Carmel, R. (1999). Mild cobalamin deficiency in older Dutch subjects. *Am. J. Clin. Nutr.* 69, 738–739.
- Carmel, R. (2000). Current concepts in cobalamin deficiency. *Annu. Rev. Med.* 51, 357–375. doi: 10.1146/annurev.med.51.1.357
- Carmel, R. (2011). Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II. *Am. J. Clin. Nutr.* 94, 348S–358S. doi: 10.3945/ajcn.111.013441
- Carmel, R. (2012). Subclinical cobalamin deficiency. *Curr. Opin. Gastroenterol.* 28, 151–158. doi: 10.1097/MOG.0b013e3283505852
- Carmel, R. (2013). Diagnosis and management of clinical and subclinical cobalamin deficiencies: why controversies persist in the age of sensitive metabolic testing. *Biochimie* 95, 1047–1055. doi: 10.1016/j.biochi.2013.02.008
- Clarke, R., Refsum, H., Birks, J., Evans, J. G., Johnston, C., Sherliker, P., et al. (2003). Screening for vitamin B-12 and folate deficiency in older persons. *Am. J. Clin. Nutr.* 77, 1241–1247.
- Davey, G. K., Spencer, E. A., Appleby, P. N., Allen, N. E., Knox, K. H., and Key, T. J. (2003). EPIC-Oxford: lifestyle characteristics and nutrient intakes in a cohort of 33 883 meat-eaters and 31 546 non meat-eaters in the UK. *Public Health Nutr.* 6, 259–269. doi: 10.1079/PHN2002430
- Dayaldasani, A., Ruiz-Escalera, J., Rodriguez-Espinosa, M., Rueda, I., Perez-Valero, V., and Yahyaoui, R. (2014). Serum vitamin B₁₂ levels during the first trimester of pregnancy correlate with newborn screening markers of vitamin B₁₂ deficiency. *Int. J. Vitam. Nutr. Res.* 84, 92–97. doi: 10.1024/0300-9831/a000196
- de Benoist, B. (2008). Conclusions of a WHO technical consultation on folate and vitamin B₁₂ deficiencies. *Food Nutr. Bull.* 29, S238–S244. doi: 10.1177/15648265080292S129
- de Jager, J., Kooy, A., Leher, P., Wulfelle, M. G., Van Der Kolk, J., Bets, D., et al. (2010). Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. *BMJ* 340:c2181. doi: 10.1136/bmj.c2181
- Devalia, V., Hamilton, M. S., Molloy, A. M., and British Committee for Standards in Haematology (2014). Guidelines for the diagnosis and treatment of cobalamin and folate disorders. *Br. J. Haematol.* 166, 496–513. doi: 10.1111/bjh.12959
- Dror, D. K., and Allen, L. H. (2008). Effect of vitamin B₁₂ deficiency on neurodevelopment in infants: current knowledge and possible mechanisms. *Nutr. Rev.* 66, 250–255. doi: 10.1111/j.1753-4887.2008.00031.x
- Duggan, C., Srinivasan, K., Thomas, T., Samuel, T., Rajendran, R., Muthayya, S., et al. (2014). Vitamin B-12 supplementation during pregnancy and early lactation increases maternal, breast milk, and infant measures of vitamin B-12 status. *J. Nutr.* 144, 758–764. doi: 10.3945/jn.113.187278
- Dutchak, P. A., Laxman, S., Estill, S. J., Wang, C., Wang, Y., Wang, Y., et al. (2015). Regulation of Hematopoiesis and Methionine Homeostasis by mTORC1 Inhibitor NPRL2. *Cell Rep.* 12, 371–379. doi: 10.1016/j.celrep.2015.06.042
- Fedosov, S. N. (2012). Physiological and molecular aspects of cobalamin transport. *Subcell. Biochem.* 56, 347–367. doi: 10.1007/978-94-007-2199-9_18
- Fedosov, S. N. (2013). Biochemical markers of vitamin B₁₂ deficiency combined in one diagnostic parameter: the age-dependence and association with cognitive function and blood hemoglobin. *Clin. Chim. Acta* 422, 47–53. doi: 10.1016/j.cca.2013.04.002
- Fedosov, S. N., Brito, A., Miller, J. W., Green, R., and Allen, L. H. (2015). Combined indicator of vitamin B₁₂ status: modification for missing biomarkers and folate status and recommendations for revised cut-points. *Clin. Chem. Lab. Med.* 53, 1215–1225. doi: 10.1515/cclm-2014-0818
- Fedosov, S. N., Fedosova, N. U., Krautler, B., Nexo, E., and Petersen, T. E. (2007). Mechanisms of discrimination between cobalamins and their natural analogues during their binding to the specific B₁₂-transporting proteins. *Biochemistry* 46, 6446–6458. doi: 10.1021/bi062063l
- Finkelstein, J. D., and Martin, J. J. (1984). Methionine metabolism in mammals. Distribution of homocysteine between competing pathways. *J. Biol. Chem.* 259, 9508–9513.
- Fokkema, M. R., Woltil, H. A., Van Beusekom, C. M., Schaafsma, A., Dijk-Brouwer, D. A., and Muskiet, F. A. (2002). Plasma total homocysteine increases from day 20 to 40 in breastfed but not formula-fed low-birthweight infants. *Acta Paediatr.* 91, 507–511. doi: 10.1111/j.1651-2227.2002.tb03268.x
- Ford, C., Rendle, M., Tracy, M., Richardson, V., and Ford, H. (1996). Vitamin B₁₂ levels in human milk during the first nine months of lactation. *Int. J. Vitam. Nutr. Res.* 66, 329–331.
- Frery, N., Huel, G., Leroy, M., Moreau, T., Savard, R., Blot, P., et al. (1992). Vitamin B₁₂ among parturients and their newborns and its relationship with birthweight. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 45, 155–163. doi: 10.1016/0028-2243(92)90076-B
- Froese, D. S., and Gravel, R. A. (2010). Genetic disorders of vitamin B(1)(2) metabolism: eight complementation groups—eight genes. *Expert Rev. Mol. Med.* 12, e37. doi: 10.1017/S1462399410001651
- Gilsing, A. M., Crowe, F. L., Lloyd-Wright, Z., Sanders, T. A., Appleby, P. N., Allen, N. E., et al. (2010). Serum concentrations of vitamin B₁₂ and folate in British male omnivores, vegetarians and vegans: results from a cross-sectional analysis of the EPIC-Oxford cohort study. *Eur. J. Clin. Nutr.* 64, 933–939. doi: 10.1038/ejcn.2010.142
- Giugliani, E. R., Jorge, S. M., and Goncalves, A. L. (1985). Serum vitamin B₁₂ levels in parturients, in the intervillous space of the placenta and in full-term newborns and their interrelationships with folate levels. *Am. J. Clin. Nutr.* 41, 330–335.
- Green, R. (2012). Anemias beyond B₁₂ and iron deficiency: the buzz about other B's, elementary, and nonelementary problems. *Hematol. Am. Soc. Hematol. Educ. Prog.* 2012, 492–498. doi: 10.1182/asheducation-2012.1.492
- Greibe, E., Lildballe, D. L., Streym, S., Vestergaard, P., Rejnmark, L., Mosekilde, L., et al. (2013a). Cobalamin and haptocorrin in human milk and cobalamin-related variables in mother and child: a 9-mo longitudinal study. *Am. J. Clin. Nutr.* 98, 389–395. doi: 10.3945/ajcn.113.058479
- Greibe, E., Miller, J. W., Foutouhi, S. H., Green, R., and Nexo, E. (2013b). Metformin increases liver accumulation of vitamin B₁₂ - an experimental study in rats. *Biochimie* 95, 1062–1065. doi: 10.1016/j.biochi.2013.02.002
- Greibe, E., Trolle, B., Bor, M. V., Lauszus, F. F., and Nexo, E. (2013c). Metformin lowers serum cobalamin without changing other markers of cobalamin status: a study on women with polycystic ovary syndrome. *Nutrients* 5, 2475–2482. doi: 10.3390/nu5072475
- Grober, U., Kisters, K., and Schmidt, J. (2013). Neuroenhancement with vitamin B₁₂-underestimated neurological significance. *Nutrients* 5, 5031–5045. doi: 10.3390/nu5125031
- Guttormsen, A. B., Refsum, H., and Ueland, P. M. (1994). The interaction between nitrous oxide and cobalamin. Biochemical effects and clinical consequences. *Acta Anaesthesiol. Scand.* 38, 753–756. doi: 10.1111/j.1399-6576.1994.tb03996.x
- Hannibal, L., Dibello, P. M., and Jacobsen, D. W. (2013). Proteomics of vitamin B₁₂ processing. *Clin. Chem. Lab. Med.* 51, 477–488. doi: 10.1515/cclm-2012-0568
- Hannibal, L., Kim, J., Brasch, N. E., Wang, S., Rosenblatt, D. S., Banerjee, R., et al. (2009). Processing of alkylcobalamins in mammalian cells: A role for the MMACHC (cblC) gene product. *Mol. Genet. Metab.* 97, 260–266. doi: 10.1016/j.ymgme.2009.04.005
- Hartmann, B. (2008). *Nationale Verzehrsstudie II (National Nutrition Survey II)*. Available online at: <https://www.mri.bund.de/de/institute/ernaehrungsverhalten/forschungsprojekte/nvsi/> (Accessed June, 2016).
- Hartmann, H., Das, A. M., and Lucke, T. (2009). Correspondence (letter to the editor): Risk group includes infants. *Dtsch. Arztebl. Int.* 106, 290–291; author reply 291. doi: 10.3238/arztebl.2009.0291
- Hay, G., Johnston, C., Whitelaw, A., Trygg, K., and Refsum, H. (2008). Folate and cobalamin status in relation to breastfeeding and weaning in healthy infants. *Am. J. Clin. Nutr.* 88, 105–114.
- Health Quality Ontario (2013). Vitamin B₁₂ and cognitive function: an evidence-based analysis. *Ont. Health Technol. Assess. Ser.* 13, 1–45.
- Heinzl, S. (2014). Vitamin-B₁₂-mangel: protonenpumpenhemmer und H₂-blocker als auslöser. *Dtsch. Arztebl. Int.* 111, 353–354.
- Herrmann, W., and Obeid, R. (2008). Ursachen und frühzeitige Diagnostik von Vitamin-B₁₂-Mangel. *Dtsch Arztebl Int.* 105, 680–685.
- Herrmann, W., and Obeid, R. (2013). Utility and limitations of biochemical markers of vitamin B₁₂ deficiency. *Eur. J. Clin. Invest.* 43, 231–237. doi: 10.1111/eci.12034

- Hinton, C. F., Ojodu, J. A., Fernhoff, P. M., Rasmussen, S. A., Scanlon, K. S., and Hannon, W. H. (2010). Maternal and neonatal vitamin B₁₂ deficiency detected through expanded newborn screening—United States, 2003–2007. *J. Pediatr.* 157, 162–163. doi: 10.1016/j.jpeds.2010.03.006
- Hoffmann-Lucke, E., Arendt, J. F., Nissen, P. H., Mikkelsen, G., Aasly, J. O., and Nexo, E. (2013). Three family members with elevated plasma cobalamin, transcobalamin and soluble transcobalamin receptor (sCD320). *Clin. Chem. Lab. Med.* 51, 677–682. doi: 10.1515/cclm-2012-0554
- Hogeveen, M., Den Heijer, M., Schonbeck, Y., Ijland, M., Van Oppenraaij, D., Gunnewiek, J. K., et al. (2010). The effect of folic acid supplementation on homocysteine concentrations in newborns. *Eur. J. Clin. Nutr.* 64, 1266–1271. doi: 10.1038/ejcn.2010.155
- Holzvelova, E., Vonarbourg, C., Stolzenberg, M. C., Arkwright, P. D., Selz, F., Prieur, A. M., et al. (2004). Autoimmune lymphoproliferative syndrome with somatic Fas mutations. *N. Engl. J. Med.* 351, 1409–1418. doi: 10.1056/NEJMoa040036
- Howden, C. W. (2000). Vitamin B₁₂ levels during prolonged treatment with proton pump inhibitors. *J. Clin. Gastroenterol.* 30, 29–33. doi: 10.1097/00004836-20001000-00006
- Huemer, M., Kozič, V., Rinaldo, P., Baumgartner, M. R., Merinero, B., Pasquini, E., et al. (2015). Newborn screening for homocystinurias and methylation disorders: systematic review and proposed guidelines. *J. Inherit. Metab. Dis.* 38, 1007–1019. doi: 10.1007/s10545-015-9830-z
- Institute of Medicine (Us) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and Its Panel on Folate, Other B Vitamins, and Choline (1998). *Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline*. Washington, DC: National Academy Press.
- Iqbal, N., Azar, D., Yun, Y. M., Ghausi, O., Ix, J., and Fitzgerald, R. L. (2013). Serum methylmalonic acid and holotranscobalamin-II as markers for vitamin B₁₂ deficiency in end-stage renal disease patients. *Ann. Clin. Lab. Sci.* 43, 243–249.
- Jackson, C. E., Fischer, R. E., Hsu, A. P., Anderson, S. M., Choi, Y., Wang, J., et al. (1999). Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. *Am. J. Hum. Genet.* 64, 1002–1014. doi: 10.1086/302333
- Jacobsen, D. W., Gatautis, V. J., Green, R., Robinson, K., Savon, S. R., Secic, M., et al. (1994). Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. *Clin. Chem.* 40, 873–881.
- Jacques, P. F., Selhub, J., Bostom, A. G., Wilson, P. W., and Rosenberg, I. H. (1999). The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N. Engl. J. Med.* 340, 1449–1454. doi: 10.1056/NEJM199905133401901
- Jiang, W., Nakayama, Y., Sequeira, J. M., and Quadros, E. V. (2013). Mapping the functional domains of TCIBR/CD320, the receptor for cellular uptake of transcobalamin-bound cobalamin. *FASEB J.* 27, 2988–2994. doi: 10.1096/fj.13-230185
- Keller, P., Rufener, J., Schild, C., Fedosov, S. N., Nissen, P. H., and Nexo, E. (2016). False low holotranscobalamin levels in a patient with a novel TCN2 mutation. *Clin. Chem. Lab. Med.* doi: 10.1515/cclm-2016-0063. [Epub ahead of print].
- Koch, C. A. (2009). Correspondence (letter to the editor): Gastrin levels in pernicious anemia. *Dtsch. Arztebl. Int.* 106:290. doi: 10.3238/arztebl.2009.0290a
- Kristensen, N. B., Madsen, M. L., Hansen, T. H., Allin, K. H., Hoppe, C., Fagt, S., et al. (2015). Intake of macro- and micronutrients in Danish vegans. *Nutr. J.* 14, 115. doi: 10.1186/s12937-015-0103-3
- Kumar, N. (2014). Neurologic aspects of cobalamin (B₁₂) deficiency. *Handb. Clin. Neurol.* 120, 915–926. doi: 10.1016/B978-0-7020-4087-0.00060-7
- Kwon, Y., Kim, H. J., Lo Menzo, E., Park, S., Szomstein, S., and Rosenthal, R. J. (2014). Anemia, iron and vitamin B₁₂ deficiencies after sleeve gastrectomy compared to Roux-en-Y gastric bypass: a meta-analysis. *Surg. Obes. Relat. Dis.* 10, 589–597. doi: 10.1016/j.soard.2013.12.005
- Lemberger, T., Saladin, R., Vazquez, M., Assimacopoulos, F., Staels, B., Desvergne, B., et al. (1996). Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. *J. Biol. Chem.* 271, 1764–1769. doi: 10.1074/jbc.271.3.1764
- Leung, S., Mattman, A., Snyder, F., Kassam, R., Meneilly, G., and Nexo, E. (2010). Metformin induces reductions in plasma cobalamin and haptocorrin bound cobalamin levels in elderly diabetic patients. *Clin. Biochem.* 43, 759–760. doi: 10.1016/j.clinbiochem.2010.02.011
- Levin, J., Botzel, K., Giese, A., Vogeser, M., and Lorenzl, S. (2010). Elevated levels of methylmalonate and homocysteine in Parkinson's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis. *Dement. Geriatr. Cogn. Disord.* 29, 553–559. doi: 10.1159/000314841
- Lewerin, C., Ljungman, S., and Nilsson-Ehle, H. (2007). Glomerular filtration rate as measured by serum cystatin C is an important determinant of plasma homocysteine and serum methylmalonic acid in the elderly. *J. Intern. Med.* 261, 65–73. doi: 10.1111/j.1365-2796.2006.01732.x
- Lildballe, D. L., Hardlei, T. F., Allen, L. H., and Nexo, E. (2009). High concentrations of haptocorrin interfere with routine measurement of cobalamins in human serum and milk. A problem and its solution. *Clin. Chem. Lab. Med.* 47, 182–187. doi: 10.1515/CCLM.2009.047
- Liu, Q., Li, S., Quan, H., and Li, J. (2014). Vitamin B₁₂ status in metformin treated patients: systematic review. *PLoS ONE* 9:e100379. doi: 10.1371/journal.pone.0100379
- Luhby, A. L., Cooperman, J. M., Stone, M. L., and Slobody, L. B. (1958). Physiology of vitamin B₁₂ in pregnancy, the placenta, and the newborn. *Am. J. Dis. Child* 96, 127–128.
- Lysne, V., Strand, E., Svingen, G. F. T., Bjørndal, B., Pedersen, E. R., Midttun, Ø., et al. (2016). Peroxisome proliferator-activated receptor activation is associated with altered plasma one-carbon metabolites and B-vitamin status in rats. *Nutrients* 8:26. doi: 10.3390/nu8010026
- Magerus-Chatinet, A., Stolzenberg, M. C., Loffredo, M. S., Neven, B., Schaffner, C., Ducrot, N., et al. (2009). FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. *Blood* 113, 3027–3030. doi: 10.1182/blood-2008-09-179630
- Majumder, S., Soriano, J., Louie Cruz, A., and Dasanu, C. A. (2013). Vitamin B₁₂ deficiency in patients undergoing bariatric surgery: preventive strategies and key recommendations. *Surg. Obes. Relat. Dis.* 9, 1013–1019. doi: 10.1016/j.soard.2013.04.017
- Marcadier, J. L., Smith, A. M., Pohl, D., Schwartzentruber, J., Al-Dirbashi, O. Y., Consortium, F. C., et al. (2013). Mutations in ALDH6A1 encoding methylmalonate semialdehyde dehydrogenase are associated with dysmyelination and transient methylmalonic aciduria. *Orphanet J. Rare Dis.* 8:98. doi: 10.1186/1750-1172-8-98
- Marcuard, S. P., Sinar, D. R., Swanson, M. S., Silverman, J. F., and Levine, J. S. (1989). Absence of luminal intrinsic factor after gastric bypass surgery for morbid obesity. *Dig. Dis. Sci.* 34, 1238–1242. doi: 10.1007/BF01537272
- McPhee, A. J., Davidson, G. P., Leahy, M., and Beare, T. (1988). Vitamin B₁₂ deficiency in a breast fed infant. *Arch. Dis. Child.* 63, 921–923. doi: 10.1136/adc.63.8.921
- Miles, L. M., Mills, K., Clarke, R., and Dangour, A. D. (2015). Is there an association of vitamin B₁₂ status with neurological function in older people? A systematic review. *Br. J. Nutr.* 114, 503–508. doi: 10.1017/S0007114515002226
- Miller, J. W., Garrod, M. G., Allen, L. H., Haan, M. N., and Green, R. (2009). Metabolic evidence of vitamin B-12 deficiency, including high homocysteine and methylmalonic acid and low holotranscobalamin, is more pronounced in older adults with elevated plasma folate. *Am. J. Clin. Nutr.* 90, 1586–1592. doi: 10.3945/ajcn.2009.27514
- Miller, R. K., Faber, W., Asai, M., D'gregorio, R. P., Ng, W. W., Shah, Y., et al. (1993). The role of the human placenta in embryonic nutrition. Impact of environmental and social factors. *Ann. N.Y. Acad. Sci.* 678, 92–107. doi: 10.1111/j.1749-6632.1993.tb26112.x
- Minet, J. C., Bisse, E., Aebischer, C. P., Beil, A., Wieland, H., and Lutschg, J. (2000). Assessment of vitamin B-12, folate, and vitamin B-6 status and relation to sulfur amino acid metabolism in neonates. *Am. J. Clin. Nutr.* 72, 751–757.
- Mirkazemi, C., Peterson, G. M., Tenni, P. C., and Jackson, S. L. (2012). Vitamin B₁₂ deficiency in Australian residential aged care facilities. *J. Nutr. Health Aging* 16, 277–280. doi: 10.1007/s12603-011-0348-2
- Molloy, A. M., Pangilinan, F., Mills, J. L., Shane, B., O'Neill, M. B., McGaughey, D. M., et al. (2016). A common polymorphism in HIBCH influences methylmalonic acid concentrations in blood independently of cobalamin. *Am. J. Hum. Genet.* 98, 869–882. doi: 10.1016/j.ajhg.2016.03.005
- Monsen, A. L., Refsum, H., Markestad, T., and Ueland, P. M. (2003). Cobalamin status and its biochemical markers methylmalonic acid and homocysteine in

- different age groups from 4 days to 19 years. *Clin. Chem.* 49, 2067–2075. doi: 10.1373/clinchem.2003.019869
- Moore, E. M., Ames, D., Mander, A. G., Carne, R. P., Brodaty, H., Woodward, M. C., et al. (2014). Among vitamin B₁₂ deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts. *J. Alzheimers. Dis.* 39, 661–668. doi: 10.3233/JAD-131265
- Moore, E., Mander, A., Ames, D., Carne, R., Sanders, K., and Watters, D. (2012). Cognitive impairment and vitamin B₁₂: a review. *Int. Psychogeriatr.* 24, 541–556. doi: 10.1017/S1041610211002511
- Morris, M. S., Jacques, P. F., Rosenberg, I. H., and Selhub, J. (2007). Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. *Am. J. Clin. Nutr.* 85, 193–200.
- Muller, T. (2009). Possible treatment concepts for the levodopa-related hyperhomocysteinemia. *Cardiovasc. Psychiatry Neurol.* 2009:969752. doi: 10.1155/2009/969752
- Muller, T., Van Laar, T., Cornblath, D. R., Odin, P., Klostermann, F., Grandas, F. J., et al. (2013). Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. *Parkinsonism Relat. Disord.* 19, 501–507. discussion: 501. doi: 10.1016/j.parkreldis.2013.02.006
- Nagata, S., and Golstein, P. (1995). The Fas death factor. *Science* 267, 1449–1456. doi: 10.1126/science.7533326
- Nexo, E., Christensen, A. L., Petersen, T. E., and Fedosov, S. N. (2000). Measurement of transcobalamin by ELISA. *Clin. Chem.* 46, 1643–1649.
- Nexo, E., Hvas, A. M., Bleie, O., Refsum, H., Fedosov, S. N., Vollset, S. E., et al. (2002). Holo-transcobalamin is an early marker of changes in cobalamin homeostasis. A randomized placebo-controlled study. *Clin. Chem.* 48, 1768–1771.
- Obeid, R. (2014). Metformin causing vitamin B₁₂ deficiency: a guilty verdict without sufficient evidence. *Diabetes Care* 37, e22–e23. doi: 10.2337/dc13-2278
- Obeid, R., Jung, J., Falk, J., Herrmann, W., Geisel, J., Friesenhahn-Ochs, B., et al. (2013). Serum vitamin B₁₂ not reflecting vitamin B₁₂ status in patients with type 2 diabetes. *Biochimie* 95, 1056–1061. doi: 10.1016/j.biochi.2012.10.028
- Obeid, R., Morkbak, A. L., Munz, W., Nexø, E., and Herrmann, W. (2006). The cobalamin-binding proteins transcobalamin and haptocorrin in maternal and cord blood sera at birth. *Clin. Chem.* 52, 263–269. doi: 10.1373/clinchem.2005.057810
- Oliveira, J. B. (2013). The expanding spectrum of the autoimmune lymphoproliferative syndromes. *Curr. Opin. Pediatr.* 25, 722–729. doi: 10.1097/mop.0000000000000032
- Oliveira, J. B., Bleesing, J. J., Dianzani, U., Fleisher, T. A., Jaffe, E. S., Lenardo, M. J., et al. (2010). Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. *Blood* 116, e35–e40. doi: 10.1182/blood-2010-04-280347
- Palacios, G., Sola, R., Barrios, L., Pietrzik, K., Castillo, M. J., and Gonzalez-Gross, M. (2013). Algorithm for the early diagnosis of vitamin B₁₂ deficiency in elderly people. *Nutr. Hosp.* 28, 1447–1452. doi: 10.3305/nh.2013.28.5.6821
- Pawlak, R., Lester, S. E., and Babatunde, T. (2014). The prevalence of cobalamin deficiency among vegetarians assessed by serum vitamin B₁₂: a review of literature. *Eur. J. Clin. Nutr.* 68, 541–548. doi: 10.1038/ejcn.2014.46
- Pawlak, R., Parrott, S. J., Raj, S., Cullum-Dugan, D., and Lucas, D. (2013). How prevalent is vitamin B(12) deficiency among vegetarians? *Nutr. Rev.* 71, 110–117. doi: 10.1111/nure.12001
- Perez-D'gregorio, R. E., and Miller, R. K. (1998). Transport and endogenous release of vitamin B₁₂ in the dually perfused human placenta. *J. Pediatr.* 132, S35–S42. doi: 10.1016/s0022-3476(98)70526-8
- Porck, H. J., Frater-Schroder, M., Frants, R. R., Kierat, L., and Eriksson, A. W. (1983). Genetic evidence for fetal origin of transcobalamin II in human cord blood. *Blood* 62, 234–237.
- Pupavac, M., Tian, X., Chu, J., Wang, G., Feng, Y., Chen, S., et al. (2016). Added value of next generation gene panel analysis for patients with elevated methylmalonic acid and no clinical diagnosis following functional studies of vitamin B₁₂ metabolism. *Mol. Genet. Metab.* 117, 363–368. doi: 10.1016/j.ymgme.2016.01.008
- Quadros, E. V., and Sequeira, J. M. (2013). Cellular uptake of cobalamin: transcobalamin and the TCblR/CD320 receptor. *Biochimie* 95, 1008–1018. doi: 10.1016/j.biochi.2013.02.004
- Quadros, E. V., Lai, S. C., Nakayama, Y., Sequeira, J. M., Hannibal, L., Wang, S., et al. (2010). Positive newborn screen for methylmalonic aciduria identifies the first mutation in TCblR/CD320, the gene for cellular uptake of transcobalamin-bound vitamin B(12). *Hum. Mutat.* 31, 924–929. doi: 10.1002/humu.21297
- Quadros, E. V., Nakayama, Y., and Sequeira, J. M. (2009). The protein and the gene encoding the receptor for the cellular uptake of transcobalamin-bound cobalamin. *Blood* 113, 186–192. doi: 10.1182/blood-2008-05-158949
- Rasmussen, K., Moller, J., Lyngbak, M., Pedersen, A. M., and Dybkjaer, L. (1996). Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. *Clin. Chem.* 42, 630–636.
- Rasmussen, S. A., Fernhoff, P. M., and Scanlon, K. S. (2001). Vitamin B₁₂ deficiency in children and adolescents. *J. Pediatr.* 138, 10–17. doi: 10.1067/mpd.2001.112160
- Refsum, H., Yajnik, C. S., Gadkari, M., Schneede, J., Vollset, S. E., Orning, L., et al. (2001). Hyperhomocysteinemia and elevated methylmalonic acid indicate a high prevalence of cobalamin deficiency in Asian Indians. *Am. J. Clin. Nutr.* 74, 233–241.
- Remacha, A. F., Sarda, M. P., Canals, C., Queralto, J. M., Zapico, E., Remacha, J., et al. (2013). Combined cobalamin and iron deficiency anemia: a diagnostic approach using a model based on age and homocysteine assessment. *Ann. Hematol.* 92, 527–531. doi: 10.1007/s00277-012-1634-8
- Remacha, A. F., Sarda, M. P., Canals, C., Queralto, J. M., Zapico, E., Remacha, J., et al. (2014). Role of serum holotranscobalamin (holoTC) in the diagnosis of patients with low serum cobalamin. Comparison with methylmalonic acid and homocysteine. *Ann. Hematol.* 93, 565–569. doi: 10.1007/s00277-013-1905-z
- Riedel, B. M., Molloy, A. M., Meyer, K., Fredriksen, A., Ulvik, A., Schneede, J., et al. (2011). Transcobalamin polymorphism 67A->G, but not 776C->G, affects serum holotranscobalamin in a cohort of healthy middle-aged men and women. *J. Nutr.* 141, 1784–1790. doi: 10.3945/jn.111.141960
- Riedel, B., Bjørk Mønsen, A. L., Ueland, P. M., and Schneede, J. (2005). Effects of oral contraceptives and hormone replacement therapy on markers of cobalamin status. *Clin. Chem.* 51, 778–781. doi: 10.1373/clinchem.2004.043828
- Rieux-Laucat, F., Fischer, A., and Deist, F. L. (2003). Cell-death signaling and human disease. *Curr. Opin. Immunol.* 15, 325–331. doi: 10.1016/S0952-7915(03)00042-6
- Risch, M., Meier, D. W., Sakem, B., Medina Escobar, P., Risch, C., Nydegger, U., et al. (2015). Vitamin B₁₂ and folate levels in healthy Swiss senior citizens: a prospective study evaluating reference intervals and decision limits. *BMC Geriatr.* 15:82. doi: 10.1186/s12877-015-0060-x
- Rizzo, N. S., Jaceldo-Siegl, K., Sabate, J., and Fraser, G. E. (2013). Nutrient profiles of vegetarian and nonvegetarian dietary patterns. *J. Acad. Nutr. Diet.* 113, 1610–1619. doi: 10.1016/j.jand.2013.06.349
- Sarafoglou, K., Rodgers, J., Hietala, A., Matern, D., and Bentler, K. (2011). Expanded newborn screening for detection of vitamin B₁₂ deficiency. *JAMA* 305, 1198–1200. doi: 10.1001/jama.2011.310
- Schedvin, G., Jones, I., Hultdin, J., and Nilsson, T. K. (2005). A laboratory algorithm with homocysteine as the primary parameter reduces the cost of investigation of folate and cobalamin deficiency. *Clin. Chem. Lab. Med.* 43, 1065–1068. doi: 10.1515/CCLM.2005.186
- Schneede, J., Dagnelie, P. C., Van Staveren, W. A., Vollset, S. E., Refsum, H., and Ueland, P. M. (1994). Methylmalonic acid and homocysteine in plasma as indicators of functional cobalamin deficiency in infants on macrobiotic diets. *Pediatr. Res.* 36, 194–201. doi: 10.1203/00006450-199408000-00010
- Schupbach, R., Wegmüller, R., Berguerand, C., Bui, M., and Herter-Aeberli, I. (2015). Micronutrient status and intake in omnivores, vegetarians and vegans in Switzerland. *Eur. J. Nutr.* doi: 10.1007/s00394-015-1079-7. [Epub ahead of print].
- Seif, A. E., Manno, C. S., Sheen, C., Grupp, S. A., and Teachey, D. T. (2010). Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. *Blood* 115, 2142–2145. doi: 10.1182/blood-2009-08-239525
- Selhub, J., Jacques, P. F., Dallal, G., Choumenkovitch, S., and Rogers, G. (2008). The use of blood concentrations of vitamins and their respective functional

- indicators to define folate and vitamin B₁₂ status. *Food Nutr. Bull.* 29, S67–S73. doi: 10.1177/156482650802925110
- Selhub, J., Morris, M. S., and Jacques, P. F. (2007). In vitamin B₁₂ deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentrations. *Proc. Natl. Acad. Sci. U.S.A.* 104, 19995–20000. doi: 10.1073/pnas.0709487104
- Shah, M., Simha, V., and Garg, A. (2006). Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. *J. Clin. Endocrinol. Metab.* 91, 4223–4231. doi: 10.1210/jc.2006-0557
- Shah, S., Wu, E., Rao, V. K., and Tarrant, T. K. (2014). Autoimmune lymphoproliferative syndrome: an update and review of the literature. *Curr. Allergy Asthma Rep.* 14, 462. doi: 10.1007/s11882-014-0462-4
- Sheen, E., and Triadafilopoulos, G. (2011). Adverse effects of long-term proton pump inhibitor therapy. *Dig. Dis. Sci.* 56, 931–950. doi: 10.1007/s10620-010-1560-3
- Singer, M. A., Lazaridis, C., Nations, S. P., and Wolfe, G. I. (2008). Reversible nitrous oxide-induced myeloneuropathy with pernicious anemia: case report and literature review. *Muscle Nerve* 37, 125–129. doi: 10.1002/mus.20840
- Sloan, J. L., Johnston, J. J., Manoli, I., Chandler, R. J., Krause, C., Carrillo-Carrasco, N., et al. (2011). Exome sequencing identifies ACSF3 as a cause of combined malonic and methylmalonic aciduria. *Nat. Genet.* 43, 883–886. doi: 10.1038/ng.908
- Solomon, L. R. (2005). Cobalamin-responsive disorders in the ambulatory care setting: unreliability of cobalamin, methylmalonic acid, and homocysteine testing. *Blood* 105, 978–985; author reply 1137. doi: 10.1182/blood-2004-04-1641
- Solomon, L. R. (2015). Functional cobalamin (vitamin B₁₂) deficiency: role of advanced age and disorders associated with increased oxidative stress. *Eur. J. Clin. Nutr.* 69, 687–692. doi: 10.1038/ejcn.2014.272
- Specker, B. L., Black, A., Allen, L., and Morrow, F. (1990a). Vitamin-B-12: low milk concentrations are related to low serum concentrations in vegetarian women and to methylmalonic aciduria in their infants. *Am. J. Clin. Nutr.* 52, 1073–1076.
- Specker, B. L., Brazzerol, W., Ho, M. L., and Norman, E. J. (1990b). Urinary methylmalonic acid excretion in infants fed formula or human milk. *Am. J. Clin. Nutr.* 51, 209–211.
- Stabler, S. P. (2012). “Vitamin B₁₂,” in *Present Knowledge in Nutrition*, eds J. W. Erdman, I. A. Macdonald, and S. H. Zeisel (Oxford, UK: Wiley-Blackwell), 343–358.
- Stockler, S., Corvera, S., Lambright, D., Fogarty, K., Nosova, E., Leonard, D., et al. (2014). Single point mutation in Rabenosyn-5 in a female with intractable seizures and evidence of defective endocytotic trafficking. *Orphanet J. Rare Dis.* 9:141. doi: 10.1186/s13023-014-0141-5
- Sumner, A. E., Chin, M. M., Abraham, J. L., Berry, G. T., Gracely, E. J., Allen, R. H., et al. (1996). Elevated methylmalonic acid and total homocysteine levels show high prevalence of vitamin B₁₂ deficiency after gastric surgery. *Ann. Intern. Med.* 124, 469–476. doi: 10.7326/0003-4819-124-5-199603010-00002
- Teachey, D. T., Manno, C. S., Axsom, K. M., Andrews, T., Choi, J. K., Greenbaum, B. H., et al. (2005). Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). *Blood* 105, 2443–2448. doi: 10.1182/blood-2004-09-3542
- Theethira, T. G., Dennis, M., and Leffler, D. A. (2014). Nutritional consequences of celiac disease and the gluten-free diet. *Expert Rev. Gastroenterol. Hepatol.* 8, 123–129. doi: 10.1586/17474124.2014.876360
- Ting, R. Z., Szeto, C. C., Chan, M. H., Ma, K. K., and Chow, K. M. (2006). Risk factors of vitamin B(12) deficiency in patients receiving metformin. *Arch. Intern. Med.* 166, 1975–1979. doi: 10.1001/archinte.166.18.1975
- Torri, G. (2010). Inhalation anesthetics: a review. *Minerva Anestesiol.* 76, 215–228.
- Torsvik, I. K., Ueland, P. M., Markestad, T., Midttun, O., and Monsen, A. L. (2015). Motor development related to duration of exclusive breastfeeding, B vitamin status and B₁₂ supplementation in infants with a birth weight between 2000–3000 g, results from a randomized intervention trial. *BMC Pediatr.* 15:218. doi: 10.1186/s12887-015-0533-2
- Torsvik, I., Ueland, P. M., Markestad, T., and Bjørke-Monsen, A. L. (2013). Cobalamin supplementation improves motor development and regurgitations in infants: results from a randomized intervention study. *Am. J. Clin. Nutr.* 98, 1233–1240. doi: 10.3945/ajcn.113.061549
- Ueland, P. M., Refsum, H., Stabler, S. P., Malinow, M. R., Andersson, A., and Allen, R. H. (1993). Total homocysteine in plasma or serum: methods and clinical applications. *Clin. Chem.* 39, 1764–1779.
- Valayannopoulos, V., Haudry, C., Serre, V., Barth, M., Boddaert, N., Arnoux, J. B., et al. (2010). New SUCLG1 patients expanding the phenotypic spectrum of this rare cause of mild methylmalonic aciduria. *Mitochondrion* 10, 335–341. doi: 10.1016/j.mito.2010.02.006
- Valdes-Ramos, R., Guadarrama-Lopez, A. L., Martinez-Carrillo, B. E., and Benitez-Arciniega, A. D. (2015). Vitamins and type 2 diabetes mellitus. *Endocr. Metab. Immune Disord. Drug Targets* 15, 54–63. doi: 10.2174/1871530314666141111103217
- Valente, E., Scott, J. M., Ueland, P. M., Cunningham, C., Casey, M., and Molloy, A. M. (2011). Diagnostic accuracy of holotranscobalamin, methylmalonic acid, serum cobalamin, and other indicators of tissue vitamin B(1)(2) status in the elderly. *Clin. Chem.* 57, 856–863. doi: 10.1373/clinchem.2010.158154
- van Amsterdam, J., Nabben, T., and Van Den Brink, W. (2015). Recreational nitrous oxide use: Prevalence and risks. *Regul. Toxicol. Pharmacol.* 73, 790–796. doi: 10.1016/j.yrtph.2015.10.017
- van Beynum, I. M., den Heijer, M., Thomas, C. M., Afman, L., Oppenraay-van Emmerzaal, D., and Blom, H. J. (2005). Total homocysteine and its predictors in Dutch children. *Am. J. Clin. Nutr.* 81, 1110–1116.
- Varbanova, M., Frauenschlager, K., and Malfertheiner, P. (2014). Chronic gastritis - an update. *Best Pract. Res. Clin. Gastroenterol.* 28, 1031–1042. doi: 10.1016/j.bpg.2014.10.005
- Vashi, P., Edwin, P., Popiel, B., Lammersfeld, C., and Gupta, D. (2016). Methylmalonic acid and homocysteine as indicators of vitamin B-12 deficiency in cancer. *PLoS ONE* 11:e0147843. doi: 10.1371/journal.pone.0147843
- Vu, T., Amin, J., Ramos, M., Flener, V., Vanyo, L., and Tisman, G. (1993). New assay for the rapid determination of plasma holotranscobalamin II levels: preliminary evaluation in cancer patients. *Am. J. Hematol.* 42, 202–211. doi: 10.1002/ajh.2830420212
- Watkins, D., and Rosenblatt, D. S. (2011). Inborn errors of cobalamin absorption and metabolism. *Am. J. Med. Genet. C Semin. Med. Genet.* 157C, 33–44. doi: 10.1002/ajmg.c.30288
- Watkins, D., and Rosenblatt, D. S. (2013). Lessons in biology from patients with inborn errors of vitamin B₁₂ metabolism. *Biochimie* 95, 1019–1022. doi: 10.1016/j.biochi.2013.01.013
- Wheeler, S. (2008). Assessment and interpretation of micronutrient status during pregnancy. *Proc. Nutr. Soc.* 67, 437–450. doi: 10.1017/S0029665108008732
- Wickramasinghe, S. N., and Ratnayaka, I. D. (1996). Limited value of serum holotranscobalamin II measurements in the differential diagnosis of macrocytosis. *J. Clin. Pathol.* 49, 755–758. doi: 10.1136/jcp.49.9.755
- Wilhelm, S. M., Rjater, R. G., and Kale-Pradhan, P. B. (2013). Perils and pitfalls of long-term effects of proton pump inhibitors. *Expert Rev. Clin. Pharmacol.* 6, 443–451. doi: 10.1586/17512433.2013.811206
- Yetley, E. A., Pfeiffer, C. M., Phinney, K. W., Bailey, R. L., Blackmore, S., Bock, J. L., et al. (2011). Biomarkers of vitamin B-12 status in NHANES: a roundtable summary. *Am. J. Clin. Nutr.* 94, 313S–321S. doi: 10.3945/ajcn.111.013243
- Zhao, H., Li, H., Ruberu, K., and Garner, B. (2015). Impaired lysosomal cobalamin transport in Alzheimer's disease. *J. Alzheimers Dis.* 43, 1017–1030. doi: 10.3233/JAD-140681

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Hannibal, Lysne, Bjørke-Monsen, Behringer, Grünert, Spiekerkoetter, Jacobsen and Blom. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.